| Identification | Back Directory | [Name]
1-Pyrrolidinecarboxylic acid, 2,2'-([1,1'-biphenyl]-4,4'-diyldi-1H-iMidazole-5,2-diyl)bis-, 1,1'-bis(1,1-diMethylethyl) ester, (2S,2'S)- | [CAS]
1007882-23-6 | [Synonyms]
(2S,2'S)-
EOS-61352
HCV-IN-30
Daclatasvir Intermediates
Daclatasvir Intermediate-2
Daclatasvir intermediate 02
Daclatasvir Intermediates Ⅱ
Dacaltasvir Intermediate 02
Daclatasvir Intermediates 4
1-Pyrrolidinecarboxylic acid, 2,2'-([1,1'-biphenyl]-4,4'-diy...
1-Pyrrolidinecarboxylic acid,2,2'-([1,1'-biphenyl]-4,4'-diyldi-1H-imidazole-5,2-diyl)bis-
Di-tert-butyl2,2'-([1,1'-biphenyl]-4,4'-diylbis(1H-imidazole-5,2-diyl))(2S,2'S)-bis(pyridineidine-1-
di-tert-butyl (2S,2'S)-2,2'-(4,4'-biphenyldiylbis(1H-imidazole-5,2-diyl))di(1-pyrrolidinecarboxylate)
di-tert-butyl2,2'-([1,1'-biphenyl]-4,4'-diylbis(1H-imidazole-5,2-diyl))(2S,2'S)-bis(pyrrolidine-1-carboxylate)
Di-tert-butyl2,2'-([1,1'-biphenyl]-4,4'-diylbis(1H-imidazole-5,2-diyl))(2S,2'S)-bis(pyridineidine-1-carboxylate)
Bis(2-methyl-2-propanyl) (2S,2'S)-2,2'-[4,4'-biphenyldiylbis(1H-imidazole-4,2-diyl)]di(1-pyrrolidinecarboxylate)
(2S,2'S)-di-tert-butyl 2,2'-(4,4'-([1,1'-biphenyl]-4,4'-diyl)bis(1H-iMidazole-4,2-diyl))bis(pyrrolidine-1-carboxylate)
(2S,2''S)-Di-tert-butyl 2,2''-(5,5''-([1,1''-biphenyl]-4,4''-diyl)bis(1h-imidazole-5,2-diyl))bis(pyrrolidine-1-carboxylate)
(2S,2'S)-2,2'-[(1,1'-biphenyl)-4,4'-diyldi-1H-imidazole-5,2-diyl]bis-1-pyrrolidinecarboxylic acid ,1,1'-bis(1,1-dimethylethyl) ester
1-Pyrrolidinecarboxylic acid, 2,2'-([1,1'-biphenyl]-4,4'-diyldi-1H-iMidazole-5,2-diyl)bis-, 1,1'-bis(1,1-diMethylethyl) ester, (2S,2'S)-
1-Pyrrolidinecarboxylic acid, 2,2'-([1,1'-biphenyl]-4,4'-diyldi-1H-iMidazole-5,2-diyl)bis-, 1,1'-bis(1,1-diMethylethyl) ester, (2S,2'S)-nyl
2-(5-(4'-(2-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-1H-imidazol-4-yl)-[1,1'-biphenyl]-4-yl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate
Methyl-N-[(2S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate | [EINECS(EC#)]
1592732-453-0 | [Molecular Formula]
C36H44N6O4 | [MDL Number]
MFCD28404669 | [MOL File]
1007882-23-6.mol | [Molecular Weight]
624.772 |
| Chemical Properties | Back Directory | [Boiling point ]
890.2±65.0 °C(Predicted) | [density ]
1.220±0.06 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
DMSO (Slightly), Methanol (Slightly) | [form ]
Solid | [pka]
12.83±0.10(Predicted) | [color ]
White to Off-White | [InChIKey]
WPMTYMFNINZZHE-WBOANQFRNA-N | [SMILES]
C1(C2=CC=C(C3NC([C@@H]4CCCN4C(OC(C)(C)C)=O)=NC=3)C=C2)=CC=C(C2NC([C@@H]3CCCN3C(OC(C)(C)C)=O)=NC=2)C=C1 |&1:8,30,r| |
| Hazard Information | Back Directory | [Uses]
(2S,2''S)-2,2''-([1,1''-Biphenyl]-4,4''-diyldi-1H-imidazole-5,2-diyl)bis-1-pyrrolidinecarboxylic Acid 1,1''-Bis(1,1-dimethylethyl) Ester is an antiviral agent and Daclatasvir (D101500) intermediate. Daclatasvir inhibits the HCV protein NS5A and thus can be used as a drug candidate for the treatment of hepatitis C (HCV). | [Synthesis]
General procedure for the synthesis of (2S,2'S)-di-tert-butyl 2,2'-(4,4'-([1,1'-biphenyl]-4,4'-diyl)bis(1H-imidazole-4,2-diyl))bis(pyrrolidine-1-carboxylate) from DACLATASVIR INTERMEDIATE - daclatasvir intermediate: a mixture of 3 (2 g, 3.01 mmol) and NH4OAc (4.65 g, 60.3 mmol) in toluene (30 mL) was heated to reflux at 130 °C for 15 hours. Upon completion of the reaction, the volatile components were removed by distillation under reduced pressure. The residue was partitioned between CH2Cl2 and H2O until saturation was reached. Saturated aqueous NaHCO3 was added to neutralize the aqueous phase. The aqueous phase was extracted with CH2Cl2, the organic phases were combined, dried over anhydrous MgSO4, filtered and concentrated under reduced pressure. The residue was purified by fast column chromatography (silica gel; 50% EtOAc/hexane as eluent) to give product 4 as a white solid (1.6 g, 85% yield). | [References]
[1] Bioorganic and Medicinal Chemistry Letters, 2015, vol. 25, # 16, p. 3147 - 3150
[2] Patent: US2009/43107, 2009, A1. Location in patent: Page/Page column 8
[3] Patent: WO2010/138368, 2010, A1. Location in patent: Page/Page column 148-149
[4] Patent: KR101508022, 2015, B1. Location in patent: Paragraph 0136-0138
[5] Patent: CN106496199, 2017, A. Location in patent: Paragraph 0043; 0061; 0070; 0071; 0072 |
| Spectrum Detail | Back Directory | [Spectrum Detail]
1-Pyrrolidinecarboxylic acid, 2,2'-([1,1'-biphenyl]-4,4'-diyldi-1H-iMidazole-5,2-diyl)bis-, 1,1'-bis(1,1-diMethylethyl) ester, (2S,2'S)-(1007882-23-6)1HNMR
|
|
|